About Us

Fresenius Kabi Global at a glance

Our product portfolio comprises of a comprehensive range of IV generic medicines, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.


About us

Fresenius Kabi employs more than 41,000 people worldwide.

With our corporate philosophy of "caring for life", we are committed​ to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

In 2021, the company reported sales of more than €7.1 billion. Fresenius Kabi AG is a wholly owned subsidiary of the  Fresenius SE & Co. KGaA healthcare group.

Key Figures 

€ in millions 2021 2020
Sales 7,193 6,976
EBITDA1 1,601 1,490
EBIT1 1,153 1,095
Net Income 1,2 778 730
Employees (Dec 31) 41,397 40,519

1 Before special terms
2  Net income attributes to shareholders of Fresenius SE & Co. KGaA